The recognition is part of the “Healthcare and Pharmaceutical Awards 2023”, held by Global Health & Pharma.
September 22nd, 2023, Kyoto, Japan – HACARUS, on a mission to bring the next generation of instruments to every industry, today announced that is has been named the “Best Medical AI Diagnostic Service Provider 2023 – East Asia”, by Global Health & Pharma, as part of the “Healthcare and Pharmaceutical Awards 2023”.
To determine the winners, Global Health & Pharma’s judging panel and research team took into consideration the commitment, expertise, and innovation shown by nominees through nomination information, voting information, supporting evidence – along with the results from an extensive period of fact-checking and research.
HACARUS solutions for the medical and life science field include HACARUS MD and HACARUS DD, with 2023 marking several significant developments, such as the market launch of “Cal.Liver.Lesion“ (an on-premise image analysis software that utilizes jointly developed AI with Bayer Yakuhin, which holds exclusive marketing rights for Cal.Liver.Lesion) and “HACARUS MD for Colposcopy” (an AI software that simplifies the storage, processing and recording of images for colposcopy using a colposcope (an instrument with a magnifying lens and a light) in response to the increasing importance of cervical cancer screening).
About HACARUS products for Medical & Life Science
Diagnosis Support AI Platform – Designed to enable the next-generation medical environment.
HACARUS MD is a diagnostic support AI platform that supports healthcare professionals. With HACARUS’s proprietary AI technology, it is possible to build highly interpretable AI without using big data. Our mission is to provide accurate and prompt diagnostic support in all medical settings.
Product Site: https://hacarus.com/medical/md/
Drug Discovery Support AI platform – Enabling a smarter approach to drug discovery
Our AI platform supports drug discovery researchers by streamlining image analysis. HACARUS’s original AI technology builds highly interpretable AI without using big data. By combining the knowledge of drug discovery researchers with AI, we will contribute to the realization of a more efficient and rapid drug discovery process.
Product Site: https://hacarus.com/medical/dd/
HACARUS INC, on a mission to bring the next generation of instruments to every industry, has since its founding in 2014, supplied AI solutions across the medical, manufacturing and construction fields in Japan – and beyond. Headquartered in Kyoto, Japan, and backed by Daikin, Osaka Gas and Miyako Capital (Kyoto University), among others, its technology enables humans to make better, faster, and more reliable decisions based on data-driven insights. HACARUS’ proprietary AI engine is built using Sparse Modeling, a method that understands data like a human would – by its unique key features and is far more resource, time, and energy-efficient when compared to Deep Learning. To learn more, visit https://hacarus.com